Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
210.13
-2.72 (-1.28%)
At close: Aug 6, 2026, 4:00 PM EDT
210.13
0.00 (0.00%)
Pre-market: Aug 7, 2026, 5:09 AM EDT
Axsome Therapeutics Stock Forecast
Stock Price Forecast
According to 21 analysts polled by S&P Global, Axsome Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $282.51. The average 1-year stock price forecast is 34.45% higher than the current stock price, while the lowest is $242 (+15.17%) and the highest is $380 (+80.84%).
Price Target: $282.51 (+34.45%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Axsome Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 17 | 17 | 17 | 17 | 17 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 21 | 21 | 21 | 21 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho Securities | Mizuho Securities | Buy Maintains $310 → $306 | Buy | Maintains | $310 → $306 | +45.62% | Jul 31, 2026 |
| BMO Capital | BMO Capital | Buy Initiates $310 | Buy | Initiates | $310 | +47.53% | Jul 20, 2026 |
| Jefferies | Jefferies | Buy Maintains $200 → $380 | Buy | Maintains | $200 → $380 | +80.84% | Jul 16, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $290 | Buy | Reiterates | $290 | +38.01% | Jul 15, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $258 | Buy | Reiterates | $258 | +22.78% | Jul 14, 2026 |
Financial Forecast
Revenue This Year
979.08M
from 638.50M
Increased by 53.34%
Revenue Next Year
1.60B
from 979.08M
Increased by 63.05%
EPS This Year
-1.82
from -3.47
EPS Next Year
5.80
from -1.82
EPS and Forward PE are based on non-GAAP adjusted numbers.